Publications

BibTex format

@inproceedings{Colombo:2022,
author = {Colombo, N and Coleman, RL and Wu, X and Kose, F and Wenham, RM and Sebastianelli, A and Hasegawa, K and Zsiros, E and Rouge, TDLM and Bidzinski, M and McNeish, IA and Sehouli, J and Korach, J and Debruyne, PR and Kim, J-W and De, Melo AC and Peng, X and Bogusz, AM and Yamada, KS and Monk, BJ},
publisher = {LIPPINCOTT WILLIAMS & WILKINS},
title = {ENGOT-ov65/KEYNOTE-B96: Phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer.},
url = {https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680305016&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb},
year = {2022}
}

Download

RIS format (EndNote, RefMan)

TY  - CPAPER
AU  - Colombo,N
AU  - Coleman,RL
AU  - Wu,X
AU  - Kose,F
AU  - Wenham,RM
AU  - Sebastianelli,A
AU  - Hasegawa,K
AU  - Zsiros,E
AU  - Rouge,TDLM
AU  - Bidzinski,M
AU  - McNeish,IA
AU  - Sehouli,J
AU  - Korach,J
AU  - Debruyne,PR
AU  - Kim,J-W
AU  - De,Melo AC
AU  - Peng,X
AU  - Bogusz,AM
AU  - Yamada,KS
AU  - Monk,BJ
PB  - LIPPINCOTT WILLIAMS & WILKINS
PY  - 2022///
SN  - 0732-183X
TI  - ENGOT-ov65/KEYNOTE-B96: Phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer.
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680305016&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
ER  -

Download

ProfessorIainMcNeish

Contact

Assistant

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)